Navigation Links
New evidence of how high glucose damages blood vessels could lead to new treatments
Date:5/11/2009

AUGUSTA, Ga. New evidence of how the elevated glucose levels that occur in diabetes damage blood vessels may lead to novel strategies for blocking the destruction, Medical College of Georgia researchers say.

They found a decreased ability of blood vessels to relax resulted from increased activity of a natural mechanism for altering protein form and function, says Dr. Rita C.Tostes, physiologist in the MCG School of Medicine.

The researchers suspect increased modification of proteins by a glucose-derived molecule is a player in vascular problems associated with hypertension, stroke and obesity as well.

One aftermath of high glucose levels is low levels of the powerful vasodilator nitric oxide in blood vessels, a shortfall that increases the risk of high blood pressure and eventual narrowing of the vessels, researchers reported at the American Society of Hypertension 24th Annual Scientific Program in San Francisco during a joint session with the Council for High Blood Pressure.

"We know diabetes is a major risk factor for cardiovascular disease and we think this is one of the reasons," Dr. Tostes says.

Diabetes increases the risk of cardiovascular disease such as heart disease and stroke, even when glucose, or blood sugar, levels are under control. In fact, about 75 percent of people with diabetes die from some form of heart or blood vessel disease, according to the American Heart Association.

Most of the glucose in the body goes directly into cells where it's modified to produce the energy source ATP. However about 5 percent of all glucose is converted to another sugar moiety, O-GlcNAc, one of the sugar types that can modify proteins.

Inside the blood vessel walls of healthy mice, MCG researchers found increased activity by O-GlcNAc competes with another mechanism for modifying proteins called phosphorylation. In blood vessels, phorphorylation modifies the enzyme that produces nitric oxide, called nitric oxide synthase, so that it makes more of the blood vessel dilator. But add more O-GlcNAc to the mix and it seems to beat phosphorylation to the punch so there is the opposite result. The longer O-GlcNAc levels were high, the worse the resulting problem, says Victor Lima, a graduate student at the University of Sao Paulo working with Dr. Tostes.

An animal model of hypertension seemed to confirm the finding that the more O-GlcNAc, the more blood vessels contract because these animals had higher O-GlcNAc levels. "Now we are trying to see why this is happening and what comes first. Is increased blood pressure leading to changed O-GlcNAc or are augmented levels of O-GlcNAc contributing to the change we see in the vasculature of hypertensives?" Dr. Tostes says. "If we know how this changes vascular function, we can understand some of the dysfunction that we see in diabetes."

To make sure they were targeting the O-GlcNAc sugar and not dealing with other effects of glucose on blood vessels, the researchers blocked the enzyme OGA, an enzyme that normally removes O-GlcNAc from proteins so they can revert to their normal state.

If the findings continue to hold true, drugs similar to those they use in the lab to inhibit OGA or OGT, the enzyme that adds O-GlcNAc to the protein, could one day help reduce the significant cardiovascular risk associated with diabetes, Mr. Lima says. "I think it looks very promising," Dr. Tostes adds.

Future studies will include blocking the pathway for adding O-GlcNAc in hypertensive animals to study the impact on blood pressure and vascular function.


'/>"/>

Contact: Toni Baker
tbaker@mcg.edu
706-721-4421
Medical College of Georgia
Source:Eurekalert  

Related biology news :

1. Princeton geoscientist offers new evidence that meteorite did not wipe out dinosaurs
2. Evidence of the Lost World -- did dinosaurs survive the end Cretaceous extinctions?
3. Fossil evidence of missing link in the origin of seals, sea lions, walruses found in Canadian Arctic
4. New evidence explains poor infant immune response to certain vaccines, says MU researcher
5. New research reveals the earliest evidence for corn in the New World
6. Researchers find the earliest evidence of domesticated maize
7. Evidence of earliest known domestic horses found in Kazakhstan
8. Polar research reveals new evidence of global environmental change
9. DNA evidence is in, newly discovered species of fish dubbed H. psychedelica
10. New lab evidence suggests preventive effect of herbal supplement in prostate cancer
11. New study provides further evidence that apple juice can delay onset of Alzheimers disease
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
New evidence of how high glucose damages blood vessels could lead to new treatments
(Date:2/2/2017)... JACKSONVILLE, Fla. , Feb. 2, 2017 /PRNewswire/ ... ), a clinical-stage immuno-oncology company specializing in the ... vaccines for the treatment of cancer and metastatic ... multi-gram scale-up and GMP manufacturing of a second ... T-cell vaccine targeting folate receptor alpha. The manufactured ...
(Date:2/2/2017)... , Feb. 1, 2017  Central to its ... meaningful advances worldwide, The Japan Prize Foundation today ... who have pushed the envelope in their respective ... Communication. Three scientists are being recognized with the ... that not only contribute to the advancement of ...
(Date:1/31/2017)... Jan. 31, 2017  Spero Therapeutics, LLC, a ... the treatment of bacterial infections, today announced it ... candidates from Pro Bono Bio Ltd (PBB) to ... multi-drug resistant forms of Gram-negative bacteria.   The assets ... Ltd, a PBB group company. "The ...
Breaking Biology News(10 mins):
(Date:2/16/2017)... HACKENSACK, N.J. , Feb. 16, 2017  Champions ... engaged in the development and sale of advanced technology ... of oncology drugs, today announced the addition of new ... These new models will expand Champions, product ... cancer, head and neck cancer, AML, and non-small cell ...
(Date:2/16/2017)... and NEW YORK , Feb. 16, ... completion of their $7M Series B financing, adding an ... the $3.5M led by Mesa Verde Venture Partners and ... resources will be directed towards further accelerating commercial adoption ... comprehensive genomic profiling test and expanding the Paradigm cancer ...
(Date:2/15/2017)... , 15. Februar 2017  Trianni, Inc. ... Biotech, Inc. (Janssen) eine Lizenzvereinbarung über die Verwendung ... Klasse führenden Plattform für die Entdeckung monoklonaler Antikörper. ... ihr neuartiges chimäres Gensegmentdesign aus, das Janssen ... humanen Antikörpern bietet und das für die schelle ...
(Date:2/15/2017)... -- Windtree Therapeutics, Inc. (Nasdaq: WINT ), ... therapies for respiratory diseases, will host a conference call ... EST on Thursday, February 16, 2017 to provide updates ... announced closing of a $10.5 million private offering and ... in the live call and take part in the ...
Breaking Biology Technology: